HOWL HOWL
Company Profile ↓Company Overview
HOWL (HOWL) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -67.58% |
| 6 Months: | -39.27% |
| 3 Months: | -40.00% |
| 1 Month: | +16.86% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)50.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 81.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.89M | -5.07M | -6.05M | -7.45M | -10.96M | -13.79M | -15.37M | -14.97M | -12.54M | -12.22M | -6.07M | -9.25M | -17.16M | -18.96M | -17.12M | -17.99M | -17.54M | -15.73M | -13.27M | 7.16M |
| Net Income | -3.83M | 2.26M | -6.07M | -7.43M | -10.92M | -13.76M | -15.34M | -14.59M | -11.94M | -11.98M | -5.10M | -8.29M | -16.19M | -17.25M | -16.67M | -18.09M | -17.98M | -16.37M | -13.53M | 3.67M |
| Diluted EPS | -4.58 | 0.22 | -6.61 | -83.36 | -3.82 | -0.51 | -0.56 | -0.53 | -0.40 | -0.34 | -0.14 | -0.23 | -0.39 | -0.43 | -0.38 | -0.40 | -0.40 | -0.36 | -0.28 | 0.08 |
| R&D Expense | 2.76M | 3.78M | 4.81M | 4.82M | 7.26M | 9.79M | 10.95M | 13.89M | 13.07M | 11.71M | 9.58M | 10.84M | 12.91M | 15.27M | 12.53M | 13.12M | 13.14M | 11.63M | 8.18M | 6.16M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -22.40M | -50.09M | -56.06M | -40.50M | -73.59M | -60.68M |
| Net Income | -15.04M | -49.98M | -53.81M | -37.37M | -70.52M | -60.82M |
| Diluted EPS | -28.08 | -10.94 | -1.86 | -1.05 | -1.63 | -1.33 |
| R&D Expense | 16.64M | 35.27M | 53.76M | 41.78M | 56.43M | 44.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 96.40M | 179.25M | 160.25M | 174.83M | 126.93M | 69.40M |
| Total Equity | -24.30M | -51.86M | 152.79M | 122.34M | 111.37M | 73.39M | 24.80M |
| Cash & Equivalents | - | 92.57M | 157.53M | 129.31M | 134.34M | 111.00M | 57.05M |
| Long Term Debt | - | - | - | - | 40.00M | 32.09M | 32.09M |
| Total Liabilities | - | 7.18M | 26.46M | 37.91M | 63.46M | 53.54M | 44.59M |
| Current Liabilities | - | 5.28M | 11.87M | 23.99M | 19.38M | 15.18M | 36.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.62M | -42.88M | -40.60M | -32.61M | -56.19M | -60.29M |
| Investing Cash Flow | -560.00K | -498.00K | -3.61M | -769.00K | -254.00K | 0 |
| Financing Cash Flow | 93.86M | 109.43M | 15.91M | 58.43M | 13.08M | 6.03M |
| Capital Expenditure | -560.00K | -498.00K | -3.61M | -769.00K | -254.00K | -0 |
| Free Cash Flow | -19.18M | -43.37M | -44.21M | -33.38M | -56.44M | -60.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 29.0% | -32.7% | -44.0% | -33.6% | -96.1% | -245.2% |
| ROCE % | -24.6% | -29.9% | -41.1% | -26.1% | -65.9% | -182.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HOWL
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics enginee…
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
– Company continues to evaluate strategic options to maximize shareholder value –WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical co…
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder valueWATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical comp…
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bod…
HOWL — Frequently Asked Questions
What is the current share price of HOWL?
As of 2026-08-05 17:25 PDT, HOWL trades at $0.40 on NASDAQ/NYSE. Its 52-week range is $0.31 to $2.19.
What is the P/E ratio of HOWL?
HOWL trades at a trailing price-to-earnings (P/E) ratio of -0.30.
Is HOWL a good stock to buy?
This page provides a data-driven analysis of HOWL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.